Tata 1mg, India’s largest integrated digital healthcare platform, has claimed that it ended FY26 as one of the only eHealth companies in India to achieve EBITDA positivity across all its established lines of business, marking a significant milestone in the company’s decade-long journey of building an integrated healthcare ecosystem.
The company said the achievement underscores the strength of its multi-vertical healthcare model, spanning ePharmacy, diagnostics, specialty pharma, retail healthcare, and digital health services.
“This year has been a real inflection point. All our core businesses turned EBITDA positive in December and sustained that momentum through Q4. This is the outcome of a decade of building an integrated healthcare model, and we are now seeing that model compound, with scale translating into both better customer experience and stronger unit economics,” said Tata 1mg Co-Founder and CEO Prashant Tandon.
ePharmacy business achieves breakeven
Tata 1mg said its ePharmacy business, currently ranked number one in India, achieved breakeven during FY26 while continuing to scale operations. The company has also expanded its express pharmacy delivery service, enabling medicine deliveries within 30-60 minutes across 10 cities.
The diagnostics vertical emerged as another major growth driver during the year. Tata 1mg said it has now entered the select group of pathology players in India operating at the ₹500-1,000 crore scale. The diagnostics business recorded over 40% year-on-year growth in FY26 while maintaining double-digit EBITDA margins.
The company currently operates 19 NABL-accredited labs serving customers across 70 cities, with its National Reference Lab also holding CAP accreditation.
Specialty pharma and D2C segments drive growth
Tata 1mg’s Specialty Pharma business, where the company holds a strong position across patient support programmes, adult vaccination, cancer care, and obesity management, registered 65% growth during FY26.
Its direct-to-consumer health products portfolio also crossed ₹200 crore in annual recurring revenue and has remained profitable since inception, according to the company.
On the offline retail front, Tata 1mg now operates 280 brick-and-mortar stores across nine clusters and plans to scale the network to 500 stores over the next 12 months as part of its omnichannel growth strategy.
“We operate in a very large market, where despite being a top player, we are not even 1% of the total market still. This gives us tremendous confidence and excitement as we work towards the phase ahead. Our vision is to build India’s most trusted integrated, omnichannel healthcare platform,” added Tandon.
AI and health intelligence to power next phase
The company said it continues to strengthen its technology and AI capabilities to drive personalized and preventive healthcare experiences.
Its Health Insights Hub and Family Hub platforms are enabling more comprehensive longitudinal consumer health tracking, while its AI-powered insights platform Pulse is currently being used by more than 75 pharmaceutical companies.
Tata 1mg said its expansion over the next 12 to 24 months will be driven by a cluster-based strategy aimed at integrating all services across key geographies while deepening supply chain capabilities.
The company identified faster pharmacy deliveries, diagnostics expansion into radiology and specialized testing, institutional partnerships in specialty care, and AI-first personalization as key growth drivers for FY27 and beyond.
“We see healthcare evolving towards being more personalised, predictive, and preventive, with trust at its core. Over the next three to five years, we aim to build India’s most trusted integrated, omnichannel healthcare platform and play a meaningful role in enabling that shift,” Tandon said.